

CORRECTION

The case against rituximab maintenance

Bruce D. Cheson

Original article Cheson, B. D. *Nat. Rev. Clin. Oncol.* **6**, 622-624 (2009); doi:10.1038/nrclinonc.2009.161

In the November 2009 issue of *Nature Reviews Clinical Oncology*, the data for estimated survival at 3 years in patients who received rituximab maintenance therapy should have read 77%, not 55%.

doi:10.1038/nrclinonc.2009.190